Learn more about Peter Attia’s digital program
First Case of Human PCSK9 Gene-Editing
Ultimately, the long-term benefits of lowering apoB through a one-time treatment may make this not only a viable future option, but potentially an intervention that could change preventive cardiovascular medicine.
Why does Alzheimer’s disease affect more women than men?
This clip is from episode #138 – Lauren Miller Rogen and Richard Isaacson, M.D.: Alzheimer’s disease prevention—patient and doctor perspectives,…
Lp(a) and CVD risk & clinical tests to measure Lp(a)
This video clip is from episode #210 – Lp(a) and its impact on heart disease with Benoît Arsenault, Ph.D., originally…
Peter’s approach to managing patients with high Lp(a)
This video is a clip from episode #210 – Lp(a) and its impact on heart disease with Benoît Arsenault, Ph.D.,…
#210 – Lp(a) and its impact on heart disease | Benoît Arsenault, Ph.D.
“I think we should advise people to measure Lp(a); that would be a gigantic step.” —Benoît Arsenault
#138 – Lauren Miller Rogen and Richard Isaacson, M.D.: Alzheimer’s disease prevention—patient and doctor perspectives
“Believe it or not, there are 46 million Americans with Alzheimer’s disease in their brain right now, but no symptoms.” — Richard Isaacson
#129 – Tom Dayspring, M.D.: The latest insights into cardiovascular disease and lipidology
“Atherogenic lipoproteins are really the issue behind clinical atherosclerotic vascular disease. … The data has just become so overwhelming.” —Tom Dayspring
#23 – Tom Dayspring, M.D., FACP, FNLA – Part IV of V: statins, ezetimibe, PCSK9 inhibitors, niacin, cholesterol and the brain
“This is what it ultimately comes down to – and it’s the way you practice – you’ve got to individualize everything.” –Tom Dayspring
Narrative glossary: lipids
A companion post for the podcast episodes with Thomas Dayspring, M.D., FACP, FNLA (October 15-19, 2018).
#03 – Ron Krauss, M.D.: a deep dive into heart disease
“Anybody interested in this field should probably understand the origins.” —Ron Krauss